← Leaderboards
Roger Stupp
Northwestern University At Chicago
$1,122,371
Attributed
$2,244,742
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,409,599 · 2
By mechanism
U19$4,164,857 · 1
R01$2,244,742 · 1
Top collaborators
- Nicholas A Butowski5 shared
- Adam M Sonabend5 shared
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Melina Rae Kibbe$9,200,692
- Rajesh Gupta$1,451,425
- Federico Ciardo$348,474
Others in their field
Other Emerging Leaders on “Operative Surgical Procedures”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,381,339
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Craig Reist · Research Triangle Institute$22,725,934
- Lisa Newman · Research Triangle Institute$22,725,934
Research focus
Operative Surgical ProceduresSafetyDesignMediatingRecurrencePreventChemotherapyCohortDoseGlioblastomaPharmaceutical PreparationsPharmacotherapyBrain NeoplasmsPre-Clinical ModelBrain TissueCellsClinical TrialsBlood - Brain Barrier AnatomyDevicesBlood-Brain Barrier DisruptionFailureFirst-In-HumanBrainSolid Neoplasm
Grant awards (10)
Advancing treatment and understanding of immunotherapy in glioblastoma$838,812
U19 · FY2025 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma$796,871
U19 · FY2024 · CA
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$337,354
R01 · FY2024 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma$821,970
U19 · FY2023 · CA
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$481,500
R01 · FY2023 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma$821,968
U19 · FY2022 · CA
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$505,516
R01 · FY2022 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma$885,236
U19 · FY2021 · CA
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$501,049
R01 · FY2021 · CA
Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma$419,323
R01 · FY2020 · CA